A study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer

Trial Identifier: D0818R00008
Sponsor: AstraZeneca
Collaborator:
Merck
NCTID:: NCT05775549
Start Date: July 2023
Primary Completion Date: October 2023
Study Completion Date: October 2023
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
US, Florida Tampa, Florida, US, 33606
US, Louisiana Shreveport, Louisiana, US, 71103
US, Maryland Annapolis, Maryland, US, 21401
US, Maryland Baltimore, Maryland, US, 21287
US, New York New York, US, 10032
US, North Carolina Charlotte, North Carolina, US, 28204
US, Wisconsin Madison, Wisconsin, US, 53792